| Biomarker ID | 1711 |
| PMID | 26172920 |
| Year | 2015 |
| Biomarker | ERG |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa (Tissue, Serum) |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.23 (95% CI: 1.01-1.49) |
| Effect on Pathways | Pathway include: Chromatin Regulation / Acetylation; Endometrial cancer; Transcriptional misregulation in cancer; TarBasePathway |
| Experiment | Recurrence Free Survival Vs No Recurrence Free Survival |
| Type of Biomarker | Prognostic |
| Cohort | 954 patients were chosen for the study out of which 435 experienced recurrenece free survival |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.04 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |